ONCOLOGY

Anti Cancer Drugs List

INJECTABLE PRODUCTS RANGE

CYTARABINE

100MG/500MG

METHOTREXATE

15MG/50MG/500MG 1000MG

VINBLASTIN

10MG

VINCRISTINE

1.2MG

DACTINOMYCINE

0.5

DAUNORUBICINE

20MG

FLUOROUARACIL

500MG /250MG

CYCLOPHOSPHAMIDE

200MG/500MG/1000MG

GRANISETRON

3ML

DACARBAZINE

200MG /500MG

BORTEZUMAB

2MG /3.05MG

BLEOMYCIN

15MG

CISPLATIN

50MG /10MG

OXALIPLATIN

50MG/100MG

GEMCITABINE

200MG/1GR

PACLITAXAL

100MG/260MG

DOCETAXAL

20MG/80MG/120MG

DOXORUBICIN

50MG /10MG

PEG DOXORUBICIN

2MG

IRINOTICAN

40MG/100MG

L-ASPRAGINSE

5000IU/10000IU

ZOLENDRONIC

ACID

AMIFOSTINE

300MG

BENDAMUSTIN

100MG

DACTINOMYCINE

0.5MG

ETOPOSIDE

100MG

FLUDARABINE

.

IFOSFOMIDE

1GR.2GR.

PEMETREXADE

100MG/500MG

PALONOSETRON

.

ONDENSETRN

.

ORAL PRODUCTS RANGE

ABIRATONE

TABLETS

METHOTREXATE

TABLETS

TAMOXIFEN

TABLETS

ANASTRAZOLE

TABLETS

LETROZOLE

TABLETS

EVEROLIUMS

TABLETS

CHLORAMBUCIL

TABLETS

APREPITANT

TABLETS

EXEMESTANE

TABLETS

CARMUSTINE

TABLETS

CAPECITABINE

TABLETS

CYCLOPHOSPHAMIDE

TABLETS

IMATINIB

TABLETS

DASTINIB

TABLETS

ERLOTINIB

TABLETS

GEFITINIB

TABLETS

TEMOZOLOMIDE

TABLETS

THALIDOMIDE

TABLETS

IBANDRONIC ACID

TABLETS

MEGESTEROL ACETATE

TABLETS

HYDROXYUREA

CAPSULES

CALCIUM LEUCOVORIN

TABLETS

Advanced Oncology Solutions

Oncology products are specialized pharmaceutical formulations designed for the prevention, diagnosis, and treatment of cancer. These products play a critical role in modern cancer care by targeting the uncontrolled growth and spread of abnormal cells, helping improve survival rates and quality of life for patients. Oncology therapies are developed using advanced scientific research and are used across various stages of cancer management, including early intervention, active treatment, and supportive care.

The oncology product portfolio includes chemotherapy agents, targeted therapies, hormonal treatments, immunotherapy drugs, and supportive oncology medicines. Chemotherapy drugs work by destroying rapidly dividing cancer cells, while targeted therapies focus on specific molecular pathways involved in tumor growth, reducing damage to healthy tissues.

INJECTABLE PRODUCTS RANGE ORAL PRODUCTS RANGE
PRODUCT NAME STRENGTH PRODUCT NAME STRENGTH
CYTARABINE100 MG / 500 MGABIRATONE250 MG, 500 MG
METHOTREXATE15 MG / 50 MG / 500 MG / 1000 MGMETHOTREXATE2.5 MG, 5 MG, 7.5 MG, 10 MG
VINBLASTIN10 MGTAMOXIFEN10 MG, 20 MG
VINCRISTINE1.2 MGANASTRAZOLE1 MG
DACTINOMYCINE0.5 MGLETROZOLE2.5 MG
DAUNORUBICINE20 MGEVEROLIUMS2.5 MG, 5 MG, 10 MG
FLUOROUARACIL500 MG / 250 MGCHLORAMBUCIL2 MG
CYCLOPHOSPHAMIDE200 MG / 500 MG / 1000 MGAPREPITANT40 MG, 80 MG, 125 MG
GRANISETRON3 MLEXEMESTANE25 MG
BORTEZUMAB2 MG / 3.05 MGCAPECITABINE150 MG, 500 MG
BLEOMYCIN15 MGCYCLOPHOSPHAMIDE50 MG
CISPLATIN50 MG / 10 MGIMATINIB100 MG, 400 MG
OXALIPLATIN50 MG / 100 MGDASTINIB20 MG, 50 MG, 70 MG, 100 MG
GEMCITABINE200 MG / 1 GRERLOTINIB25 MG, 100 MG, 150 MG
PACLITAXAL100 MG / 260 MGGEFITINIB250 MG
DOCETAXAL20 MG / 80 MG / 120 MGTEMOZOLOMIDE5 MG, 20 MG, 100 MG, 140 MG, 180 MG, 250 MG
DOXORUBICIN50 MG / 10 MGTHALIDOMIDE50 MG, 100 MG
PEG DOXORUBICIN2 MGIBANDRONIC ACID50 MG
IRINOTICAN40 MG / 100 MGMEGESTEROL ACETATE40 MG; 400 MG / 10 ML
L-ASPRAGINSE5000 IU / 10000 IUHYDROXYUREA500 MG
ZOLENDRONIC ACID—CALCIUM LEUCOVORIN5 MG, 15 MG